Yale University

TAIPEI and SAN DIEGO, March 3, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the signing of a major strategic Memorandum of Understanding (MOU) with CellType, an AI-driven biotech company backed by Y Combinator (Winter 2026). Under this partnership, the two companies will integrate CellType's proprietary AI platform to accelerate the clinical development and global commercialization strategy of Senhwa's core asset, Silmitasertib (CX-4945). Prior to formalizing the collaboration, the foundational research underlying CellType's technology was conducted at Yale University in collaboration with Google DeepMind, where researchers computationally predicted and experimentally validated a novel immune-modulatory mechanism of CX-4945. This strategic alliance marks a transformative milestone for Senhwa: CX-4945 is evolving from a single-target small molecule into a platform-enabling asset—"CX-4945 2.0." Through AI-driven deep data validation, Senhwa aims to expand potential indications, significantly enhance clinical success probability, and strengthen the asset's attractiveness for partnerships with international pharmaceutical companies for licensing discussion. In parallel, CellType will feature CX-4945 as the flagship case study of its AI platform, showcasing real-world validation results to global investors—demonstrating how AI can fundamentally transform traditional drug development models, reduce R&D risk, and amplify therapeutic value. Senhwa Chairman Benny T. Hu stated: "By integrating CellType's cutting-edge AI foundation models—capable of reasoning about biology at the cellular level, and rooted in pioneering research from Yale University and Google DeepMind—into Senhwa's clinical-stage core asset, we are not simply accelerating development—we are redefining the strategic positioning of CX-4945. This collaboration represents Senhwa's official entry into the next phase of AI-driven drug development. We highly recognize CellType's scientific excellence and global vision, and we look forward to unlocking new therapeutic possibilities for cancer patients worldwide while delivering sustainable, long-term structural value growth for our shareholders." AI-Driven Mechanistic Breakthrough CellType was founded by computational biologist Dr. David van Dijk. The company is backed by Y Combinator (Winter 2026). Its proprietary AI platform applies large language models to single-cell gene expression—the first of its kind—enabling sophisticated decoding of complex tumor microenvironment (TME) signaling. Through the original research collaboration with Google DeepMind at Yale University, researchers screened over 4,000 compounds and identified CX-4945 as a highly promising candidate. AI-predicted findings were subsequently validated in interdisciplinary laboratories at Yale University. Results indicate that beyond its known mechanism, CX-4945 demonstrates previously unrecognized immune-modulatory potential—including amplification of immune activation, enhancement of tumor antigen presentation, and conversion of "cold tumors" into "hot tumors." These properties may significantly improve immunotherapy efficacy and help overcome resistance challenges. Six-Month Pilot Program and Strategic Framework Under the MOU, the parties will initiate a six-month pilot program focused on: Indication expansion strategies, Biomarker discovery and validation, Combination therapy synergy evaluation in the context of immuno-oncology and new targets for treating different types of cancers and Establishment of an AI-driven translational validation framework. This collaboration not only position CX-4945 as a core immune-sensitizing molecule in immuno-oncology but also establishes Senhwa as CellType's founding strategic partner. The agreement preserves flexibility for deeper collaboration structures in the future, including joint ventures, co-development, or licensing arrangements. Market Opportunity and Strategic Outlook The global cancer immunotherapy market is entering a high-growth phase, with industry forecasts projecting the market to reach approximately US$305.8 billion by 2033. Despite rapid expansion, overcoming immunotherapy resistance and optimizing the tumor microenvironment remain among the most critical and value-defining challenges in oncology. This partnership extends beyond a technical pilot—it sends a clear signal to global capital markets: the valuation paradigm of CX-4945 is accelerating, and AI is emerging as a powerful multiplier of clinical success probability. Looking ahead, Senhwa and CellType will continue to deepen their collaboration, advancing CX-4945 from an innovative therapeutic candidate to a core AI-enabled immunotherapy platform asset—jointly redefining the next key inflection point in cancer immunotherapy and creating enduring value for shareholders, partners, and patients worldwide. SOURCE Senhwa Biosciences, Inc. 21% more press release views with Request a Demo

Struggling to fall asleep and stopping breathing at night may be a far riskier combo than previously thought. In a study of nearly a million veterans, researchers found that having both insomnia and sleep apnea dramatically raises the risk of hypertension and heart disease. The two conditions don’t just coexist—they interact in ways that intensify strain on the heart. Addressing sleep problems early could help prevent cardiovascular disease before it starts.Researchers at Yale School of Medicine (YSM) are drawing attention to a powerful and preventable factor in cardiovascular disease. Their findings suggest that improving sleep may play a much larger role in protecting heart health than many people realize. In a study published in the Journal of the American Heart Association, scientists analyzed data from nearly 1 million post-9/11 U.S. veterans. They discovered that adults who have both insomnia and obstructive sleep apnea face a significantly higher risk of high blood pressure and cardiovascular disease compared with those who have only one of the conditions. This combination, called comorbid insomnia and sleep apnea (COMISA), stood out as a particularly harmful risk category. "We spend an enormous amount of time managing cardiovascular disease downstream, but far less time addressing more upstream modifiable risk factors," says Allison Gaffey, PhD, assistant professor of medicine (cardiovascular medicine) at YSM and first author of the paper. "Sleep disturbances, which are common in the veteran population, are often treated as secondary problems." Insomnia and Sleep Apnea Often Overlap Doctors usually diagnose and treat insomnia and obstructive sleep apnea as separate disorders. Insomnia makes it hard to fall asleep or stay asleep. Sleep apnea involves repeated pauses in breathing during the night. However, many people experience both conditions at the same time, and when they occur together, the health effects can intensify. "These conditions don't just coexist politely," Gaffey says. "Treating one while ignoring the other is a bit like bailing water out of a boat without fixing the leak." Why Disrupted Sleep Strains the Heart The connection is important because sleep is essential for regulating the cardiovascular system. During healthy sleep, the heart and blood vessels have time to rest, repair, and reset. "Sleep touches every single part of our existence," says Andrey Zinchuk, MD, MHS, associate professor of medicine (pulmonary, critical care, and sleep medicine) at YSM and senior author of the paper. "Oftentimes, it is neglected even though it has such an important impact on our lives." When sleep is repeatedly disrupted by frequent awakenings, shorter sleep duration, or pauses in breathing, the cardiovascular system loses critical recovery time. Zinchuk explains that without this nightly reset, the heart and blood vessels cannot properly adapt and restore balance. Prevention and Early Cardiovascular Risk A key aim of the study was to determine whether sleep disorders influence cardiovascular risk early enough for prevention to make a difference. "We wanted to know whether COMISA mattered early in the cardiovascular risk trajectory," Gaffey says, "rather than decades later when disease is already established." According to Gaffey, ongoing sleep problems should not be dismissed as minor frustrations. "Over time, it places a measurable strain on your cardiovascular system," she says. Zinchuk emphasizes that future care must prioritize prevention rather than waiting to treat advanced disease. The researchers recommend evaluating sleep as routinely as other major cardiovascular risk factors. Insomnia and sleep apnea should be assessed together instead of in isolation. Because sleep problems are common, measurable, and treatable, identifying and addressing them early could significantly alter the course of cardiovascular disease.

Strong cash position at year-end 2025: $33.3 million (€28.4 million) CNS (Vafidemstat)Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNS Preparing protocol resubmission to incorporate FDA guidance on Phase III PORTICO-2 trial in aggression in BPD Ongoing expansion of Phase IIb schizophrenia trial into additional EU countries Finalizing preparations for new Phase II trial in aggression in autism spectrum disorder as a part of the IPCEI EU Grant in personalized medicine Oncology – Hematology (Iadademstat)Seven ongoing oncology trials, with six sponsored by the NCI or top-tier U.S. institutions Positive data in 1L AML unfit patients presented at ASH with 100% ORR (90% strict CR) Positive data in R/R FLT3+ AML presented at ASH; 67% CCR at the selected dose under expansion Initiated enrollment in new Phase Ib trial in small cell lung cancer in combination with ICI and radiotherapy Continued momentum in Phase Ib sickle cell disease trial with first two cohorts enrolled New Phase II trial in essential thrombocythemia approved by EMA Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNS Preparing protocol resubmission to incorporate FDA guidance on Phase III PORTICO-2 trial in aggression in BPD Ongoing expansion of Phase IIb schizophrenia trial into additional EU countries Finalizing preparations for new Phase II trial in aggression in autism spectrum disorder as a part of the IPCEI EU Grant in personalized medicine Seven ongoing oncology trials, with six sponsored by the NCI or top-tier U.S. institutions Positive data in 1L AML unfit patients presented at ASH with 100% ORR (90% strict CR) Positive data in R/R FLT3+ AML presented at ASH; 67% CCR at the selected dose under expansion Initiated enrollment in new Phase Ib trial in small cell lung cancer in combination with ICI and radiotherapy Continued momentum in Phase Ib sickle cell disease trial with first two cohorts enrolled New Phase II trial in essential thrombocythemia approved by EMA MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, February 27th, 2026 – Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today reported financial results for the twelve months ended December 31, 2025 and provided a corporate update on recent developments. “After securing over $60 million in the first half of 2025, marking a clear financial turnaround for Oryzon, we ended the year with a solid cash position of $33.3 million (€28.4 million),” said Dr. Carlos Buesa, Oryzon’s Chief Executive Officer. “This financial strength allows us to sharpen our focus on key regulatory catalysts across both of our programs: oncology and CNS.” “In oncology-hematology, iadademstat continues to receive strong external validation, with seven ongoing trials, six of which are sponsored by the NCI or leading U.S. institutions, including the most recent study sponsored by Yale University,” Dr. Buesa added. “In first-line AML, the triple combination has shown a 100% overall response rate to date, with no dose-limiting toxicities, highlighting a highly competitive profile among emerging triplet regimens. The trial continues to enroll rapidly, and we plan to present data from 15-16 patients at the European Hematology Association Annual Congress (EHA) in June. This would represent approximately 75% of the planned enrollment, providing a very meaningful interim assessment of efficacy and safety. Encouraging results are also emerging in MDS and MPN.” “In sickle cell disease, we are advancing iadademstat into what we believe represents a new paradigm for the pharmaceutical industry — medium-priced therapies addressing large patient populations. The first two cohorts of the RESTORE trial have been enrolled, and we expect to report meaningful data later this year.” “In CNS, we have further strengthened our medical and regulatory capabilities with the appointment of renowned CMO Dr. Rolando Gutierrez, who brings extensive experience from the psychiatric field to lead vafidemstat through late-stage development and regulatory interactions, particularly with the U.S. Food and Drug Administration (FDA),” continued Dr. Buesa. “Discussions with the Agency are expected to continue in the coming months, and the Company anticipates a resubmission of the Phase III protocol before year-end, in line with standard regulatory timelines. At the same time, we continue to advance our programs in schizophrenia and ASD.” Fourth Quarter and Recent Highlights Iadademstat: Vafidemstat: Earlier stage programs: Financial Update: Fourth quarter 2025 Financial Results Research and development (R&D) expenses were $5.2 million and $14.8 million for the quarter and twelve months ended December 31, 2025, compared to $2.1 and $8.7 million for the quarter and twelve months ended December 31, 2024. General and administrative expenses were $1.7 and $5.6 million for the quarter and twelve months ended December 31, 2025, compared to $0.9 and $3.7 million for the quarter and twelve months ended December 31, 2024. Net losses were $2.1 and $6.7 million for the quarter and twelve months ended December 31, 2025, compared to net losses of $1.1 and $4.6 million for the quarter and twelve months ended December 31, 2024. The result is as expected, given the biotechnology business model where companies in the development phase typically have a long-term maturation period for products and do not have recurrent income. Negative net result was $3.1 million (–$0.04 per share) for the twelve months ended December 31, 2025, compared to a negative net result of $3.7 million (–$0.06 per share) for the twelve months ended December 31, 2024. Cash, cash equivalents, and marketable securities totaled $33.3 million as of December 31, 2025.